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Aims: High-grade, poorly differentiated, infiltrative
carcinomas involving the renal sinus region often pose
challenging differential diagnostic considerations, spe-
cifically differentiation of urothelial carcinoma (UC)
from renal cell carcinoma (RCC) subtypes. Accurate
classification, especially the distinction of UC from RCC,
is critical, as therapeutic approaches differ.
Methods and results: Cluster analysis was performed
on immunohistochemical data from 18 invasive UCs,
six CDCs, two RMCs, 18 type 2 papillary renal cell
carcinomas (PRCCs) and 20 high-grade clear cell
renal cell carcinomas (CRCCs) using a broad panel of
traditional and novel immunohistochemical markers.
The initial analysis with all antibodies segregates
almost all the RCCs (45 of 46, 98%) from all the UCs
based on the lack of expression of p63 in all (100%)
RCCs, along with predominant strong expression of
paired box gene 8 (PAX8) and vimentin, predominant
lack of expression of high molecular weight cytoker-
atin (HMCK) and CK7 and variable expression of RCC,
CD10, CA1X and PAX2. All the UCs cluster together
with strong, diffuse reactivity for p63, predominant
reactivity for CK7 and high molecular weight kinin-
ogen (HMWK), and absent to minimal staining with
PAX8, RCC antigen, PAX2, alpha-methylacyl-CoA
racemase (AMACR), carbonic anhydrase IX (CAIX)
and vimentin. After removing antibodies with signif-
icant overlap and ⁄ or minimal impact, a second
analysis with a limited panel including p63, CK7,
vimentin, integrase interactor 1 (INI-1) and PAX8
was performed. Again, the majority of UCs cluster
into one group and p63 positivity separates all UCs
from RCCs.
Conclusions: Lack of INI-1 expression, noted exclu-
sively in RMCs, segregates RMCs into a separate
cluster. PAX8 is rarely positive (17%) in UC, is
commonly expressed in CDC, RMC, PRCC and CRCC
and is superior to PAX2.
Keywords: collecting duct carcinoma, immunohistochemistry, p63, PAX8, renal medullary carcinoma, urothelial
carcinoma
Abbreviations: AMACR, alpha-methylacyl-CoA racemase; CAIX, carbonic anhydrase IX; CDC, carcinoma of
collecting ducts of Bellini; CRCC, clear cell renal cell carcinoma; HMCK, high molecular weight cytokeratin; INI-1,
integrase interactor 1; PAX8, paired box gene 8; PRCC, papillary renal cell carcinoma; RCC, renal cell carcinoma;
RMC, renal medullary carcinoma; S100A1, S100 calcium-binding protein A1; TMA, tissue microarray; UC,
urothelial carcinoma
Address for correspondence: L P Kunju, MD, Department of Pathology, University of Michigan, 2G332 UH 1500 E. Medical Center Drive, Ann
Arbor, MI 48109-0602, USA. e-mail: lkunju@umich.edu
 2012 Blackwell Publishing Limited.
Histopathology 2012, 60, 597–608. DOI: 10.1111/j.1365-2559.2011.04093.x
Introduction
High-grade poorly differentiated carcinomas involving
the renal sinus region, including the renal medulla
and ⁄ or collecting duct system, are often diagnostically
challenging. The distinction of invasive high-grade
urothelial carcinoma (UC) involving the upper urinary
tract from high-grade renal cell carcinomas (RCC),
notably collecting duct renal cell carcinoma (carcinoma
of collecting ducts of Bellini, CDC) and renal medullary
carcinomas (RMC), can be especially difficult. While UC
of the upper urinary tract, CDC and RMC are usually
centred in the renal medullary ⁄ sinus region, other high-
grade RCCs, including clear cell type renal cell carci-
noma (CRCC) and papillary RCC (commonly type 2
PRCC), may extend to involve the renal sinus fat.
Although careful morphological examination will
allow for the correct diagnosis in the majority of cases,
there is sufficient overlap between these entities such
that immunohistochemistry is often required to arrive
at the correct diagnosis with confidence. Accurate
characterization of these entities, specifically distin-
guishing UC from various subtypes of RCC, is critical, as
therapeutic and prognostic implications differ.
Both CDC and RMC arise in the renal medulla and
are located in the central region of the kidney. While
CDCs are primarily high-grade adenocarcinomas with
glandular architecture and occur predominantly in
adults (mean age 55 years), RMC is a distinctive entity
occurring almost exclusively in young African Amer-
ican men (usually <30 years) with sickle cell trait.
Both these tumours are rare but biologically extremely
aggressive subtypes of RCC, with the majority of
patients presenting with metastatic disease.1,2
In recent years, needle biopsies from renal masses have
been performed increasingly.3 In these small biopsies, the
entire range of morphological features necessary to make
a diagnosis may not be appreciated fully due to sampling
issues. Immunohistochemistry is often helpful in this
setting to narrow the differential diagnosis (UC versus
RCC) and ⁄ or to arrive at a definitive diagnosis. The goal of
this study is to evaluate the utility of an optimal
immunohistochemical panel to differentiate accurately
high-grade, poorly differentiated and infiltrative carcino-
mas involving the renal sinus region, with emphasis on
distinguishing invasive UC of upper urinary tract from
high-grade RCCs, including CDC and RMC.
Materials and methods
case selection
After approval from the University of Michigan
Institutional Review Board for human subject re-
search, tumours were identified via a Systematized
Nomenclature of Medicine (SNOMED) search of the
pathology database. A total of 64 high-grade renal
tumours were identified, including 18 aggressive (pT3
or higher pathological stage) invasive UC involving
renal pelvis ⁄ upper urinary tract, six CDC, two RMC,
18 type 2 PRCC and 20 CRCC (Fuhrman nuclear
grade >3). All cases included were resection speci-
mens (radical or partial nephrectomy) and all hae-
matoxylin and eosin (H&E)-stained sections were
reviewed by study pathologists (J.C., L.P.K.) for
confirmation of the diagnosis according to the World
Health Organization (WHO) 2004 criteria.1 The
invasive high-grade UCs were classified according to
the 2004 WHO ⁄ International Society of Urological
Pathology (ISUP) classification. The cases included in
the study were a mixture of usual and diagnostically
challenging tumours.
tissue microarray (tma) construction and
cluster analysis
A TMA was constructed from 0.6-mm cores of forma-
lin-fixed, paraffin-embedded neoplastic tissue in tripli-
cate as well as representative normal kidney sections
from the same cases for controls. TMA technology is
cost-effective and allows for high-throughput immuno-
histochemical profiling of tumours in a model that
simulates small biopsy sampling. Three cores were
sampled from each case to account for tumour heter-
ogeneity. The TMA slides were stained with a select
panel of 11 antibodies using standard immunohisto-
chemical techniques on an automated Ventana Bench-
mark XT stainer (Ventana, Phoenix, AZ, USA) or a
Dako AutoStainer (Dako, Carpinteria, CA, USA). The
list of antibodies, clones, origins, titrations, pretreat-
ments, incubation times and expected staining charac-
teristics are listed in Table 1. The expression of each
antibody was characterized on a 0–2 scale, where 0
represented staining in 0% to <10% of cells, 1
represented focal expression in 10% to <50% of cells
and 2 represented diffuse expression in >50% of cells
with moderate to strong staining intensity. Scores of 1
and 2 were considered to be positive. Immunohisto-
chemical evaluation was performed independently and
blindly by two study pathologists (J.C., L.P.K.) with
expertise in genitourinary disease. Differences of opin-
ion in rare instances were resolved by consensus
evaluation of the case with all pathologists in the
study. Immunohistochemical expression results ex-
pressed as plain scores (0, 1, 2) were arranged in a
text delimited file and broadcasted from the Data Matrix
Viewer module of the gaggle software suite (http://
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gaggle.systemsbiology.org/docs) to the Multi-Experi-
ment viewer of the TM4 software suite (http://
www.tm4.org/mev.html). Unsupervised hierarchical
clustering was performed using average linkage anal-
ysis with Euclidean distance metric and the data were
divided at the second branch point down in the cluster
tree. Given the broad panel of antibodies that were
analysed, several markers were found to have overlap-
ping staining patterns or were found to have minimal
discriminating properties among the different tumour
types. After removal of these antibodies, a limited
refined panel of markers was included in a final
unsupervised cluster analysis. From this cluster plot,
the specificity and sensitivity of selected markers was
calculated for each tumour types.
Results
immunohistochemical staining patterns of
each tumour type
The results of immunostaining with all 11 antibodies
are summarized in Table 2.
Invasive UC
In contrast to high-grade RCCs, p63 was expressed
strongly and diffusely in all UC. In addition, the
majority of tumours were diffusely, strongly reactive
with both CK7 and HMCK (17 of 18, 94% each). The
majority of UC were negative with PAX8 (15 of 18,
83%) and PAX2 (17 of 18, 94%), although a small
subset of UC show predominantly focal reactivity for
PAX8 (three of 18, 17%) and PAX2 (one of 18, 6%).
All UC demonstrate complete lack of reactivity for
RCC antigen. Vimentin displayed limited expression
in 11% (two of 18) of UC, while variable positivity is
seen with CD10, alpha-methylacyl-CoA racemase
(AMACR), carbonic anhydrase IX (CAIX) and S100
calcium-binding protein A1 (S100A1). Integrase
interactor 1 (INI-1) was positive in all (100%) cases
with strong, diffuse expression. See Figure 3 and
Table 2 for details.
CDC
All the CDCs demonstrated an absolute lack of reactiv-
ity with p63 (none of six, 100%). A majority of
tumours showed diffuse, strong expression of PAX8
Table 1. List of antibodies, staining patterns and treatment conditions
Antibody Clone Staining pattern Company Dilution Pretreatment
CK7 OV-TL 12 ⁄ 30 Cytoplasmic Dako 1:50 Buffer at pH 8.0 (30 min)
p63 4A4 Nuclear Thermo Scientific, Fremont,
CA, USA
1:200 Buffer at pH 8.5 (30 min)
Vimentin V9 Cytoplasmic Dako 1:400 Buffer at pH 8.0 (30 min)
PAX8 Polyclonal Nuclear Proteintech Group, Chicago,
IL, USA
1:200 Buffer at pH 6.0 (15 min)
PAX2 Polyclonal Nuclear Zymed ⁄ Invitrogen, Carlsbad,
CA, USA
1:50 Buffer at pH 8.0 (60 min)
CD10 56C6 Cytoplasmic ⁄
membranous
Ventana, Tucson, AZ, USA Predilute Buffer at pH 8.0 (60 min)
RCC antigen PN-15 Membranous Ventana Predilute Protease 1–12 min
CAIX Polyclonal Membranous Abcam, Cambridge, MA, USA 1:200 Buffer at pH 6.0 (10 min)
HMCK 34bE12 Cytoplasmic Dako 1:50 Buffer at 8.0 (60 min)
AMACR (P504S) 13H4 Cytoplasmic Zeta, Sierra Madre, CA, USA 1:40 Buffer at pH 8.0 (30 min)
S100A1 Proprietary Cytoplasmic
or nuclear
Sigma-Aldrich, St Louis,
MO, USA
1:50 Buffer at pH 6.0 (15 min)
INI-1 MRQ-27 Nuclear Cell Marque, Rocklin, CA, USA Predilute Buffer at pH 8.0 (60 min)
AMACR, Alpha-methylacyl-CoA racemase; CAIX, carbonic anhydrase IX; HMCK, high molecular weight cytokeratin; INI-1,
integrase interactor 1; PAX, paired box gene; RCC, renal cell carcinoma; S100A1, S100 calcium-binding protein A1.
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(five of six, 83%) with a decreased sensitivity for PAX2
(three of six, 50%) and near-absent expression for RCC
antigen (one of six, 17%). CK7 was strongly positive in
half of CDCs while vimentin was expressed in 33% (two
of six) of tumours. Most of the other markers in the
panel, including HMCK, CD10, AMACR and CAIX,
were insensitive for CDC. All CDCs expressed S100A1
strongly and diffusely. Interestingly, while the majority
(66%) of CDC showed strong diffuse INI-1 expression,
33% (two of six) cases showed focal, weak expression.
See Table 2 for details.
RMC
Both cases of RMC were strongly, diffusely positive with
CK7, S100A1 and PAX 8, negative with p63, INI-1,
vimentin, CA 1X, RCC antigen and AMACR and
variably positive with PAX2 and HMCK.
CCRC
Although not specific, several markers were highly
sensitive for CRCC, including vimentin, PAX8, CD10
and CAIX, with strong diffuse expression in >90% of
the tumour for each antibody. In contrast, no CRCC
were positive for p63 or HMCK. PAX2 reactivity was
seen in 70% of CRCC. While PAX2 was less sensitive
than PAX8 (70% versus 95% tumours positive,
respectively), it was more sensitive than RCC antigen
(12 of 20, 60%). The least sensitive antibodies were
AMACR (six of 20, 30%) and CK7 (four of 20, 20%)
which mainly demonstrated focal expression. Finally,
S100A1 and INI-1 showed strong, diffuse expression in
the majority (85% and 95%, respectively) of cases.
PRCC
Among RCC subtypes, PRCC was the least sensitive for
renal markers PAX8 (78%) and PAX2 (56%), with
only half of tumours reactive with RCC antigen. The
most sensitive markers for PRCC are vimentin and
AMACR, with reactivity in 94% of tumours. Similar to
CRCC, no PRCC demonstrate reactivity with p63 or
HWCK. INI-1 was positive in all cases (100%) with
strong, diffuse expression in majority (16 of 18, 89%) of
cases. The other markers in the panel, CK7, CD10,
CAIX and S100A1, had variable staining patterns
ranging from 28% to 89%, respectively. See Figure 1
and Table 2 for details.
cluster analysis
An initial unsupervised cluster plot of the full panel of
11 antibodies segregated almost all the RCCs (45 of
46, 98%) from all the UCs based on lack of expression
of p63 in all (100%) RCCs, predominant strong
expression of PAX8 and vimentin, predominant lack
of expression with CK7 and HMCK and variable
expression of RCC antigen, CD10, CAIX and PAX2.
The tumours clustered into four distinct subgroups
(designated A–D) based on staining similarities, as
shown in Figure 1.
Group A is composed predominantly of CRCC (18 of
21, 86%), with a smaller number of PRCC (three of 21,
14%) and both tumour types demonstrate expression of
S100A1, CD10, CAIX, vimentin and INI-1 and similar
patterns of reactivity with PAX2 and PAX8. Most of the
tumours are negative for CK7 and all the tumours are
negative with p63 and HMCK. The three PRCC
tumours that segregated into group A were included
because of intense staining with CAIX. The majority of
CRCC (18 of 20, 90%) segregated into this cluster.
Group B is populated mainly by PRCC (15 of 24,
63%), a subset of CDC (three of six) as well as two
CRCC. As a cluster, these tumours are defined by
Table 2. Immunohistochemical profile of urothelial carcinoma and it morphological mimics
Percentage of cases staining positive (%)
P63 CK7 Vimentin INI-1 PAX-8 PAX-2 HMCK RCC CD10 AMACR CAIX S100A1
UC (n = 18) 100 94 11 100 17 6 94 0 50 39 33 78
CDC (n = 6) 0 50 33 100 83 50 33 17 0 33 17 100
RMC (n = 2) 0 100 0 0 100 100 50 0 0 0 0 100
PRCC (n = 18) 0 28 94 100 78 56 0 50 67 94 44 89
CRCC (n = 20) 0 20 90 100 95 70 0 60 95 30 95 85
AMACR, Alpha-methylacyl-CoA racemase; CAIX, carbonic anhydrase IX; CDC, carcinoma of collecting ducts of Bellini; CRCC,
clear cell renal cell carcinoma; HMCK, high molecular weight cytokeratin; INI-1, integrase interactor 1; PAX, paired box gene;
PRCC, capillary renal cell carcinoma; RCC, renal cell carcinoma; RMC, renal medullary carcinoma; S100A1, S100 calcium-
binding protein A1; UC, urothelial carcinoma.
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Figure 1. Initial unsupervised cluster plot of the full immunohistochemical panel. Antibodies are arrayed at the top of the map and the four
types of tumours are listed along the right side. The red line on the left is the level of the clustering tree that separates the tumours into
four groups. Almost all the renal cell carcinomas (RCCs) segregate from all the urothelial carcinomas (UCs) based on lack of expression of p63 in
all (100%) RCCs, predominant strong expression of paired box gene 8 (PAX8) and vimentin, predominant lack of expression with CK7 and
high molecular weight cytokeratin (HMCK) and variable expression of RCC, CD10, carbonic anhydrase IX (CAIX) and PAX2. The tumours
clustered into four distinct subgroups based on staining similarities. Group A illustrates those tumours driven by expression of renal markers
CD10, PAX2, PAX8, integrase interactor 1 (INI-1) and positivity with CAIX but lack of CK7, p63 and HMCK, which includes nearly all
clear cell renal cell carcinomas (CRCCs). Group B is composed of a mix of papillary renal cell carcinoma (PRCC) and half the carcinoma of
collecting ducts of Bellini (CDC) with similar expression of PAX8, PAX2, vimentin and INI-1 but decreased expression of CD10 and CAIX,
increased expression of alpha-methylacyl-CoA racemase (AMACR) and lack of p63 and HMCK. Group C is composed of tumours with similar
expressions of CK7, PAX8 and S100 calcium-binding protein A1 (S100A1), PAX8 reactivity stronger than PAX2, lack of expression with p63,
CD10, CA1X and variable expression with HMCK and INI-1 and includes both renal medullary carcinomas (RMCs) and a subset of CDC.
Both RMCs lack INI-1, vimentin and p63 expression and are strongly positive with CK7 and PAX8. Finally, group D is populated almost
exclusively by UC, which lack expression of renal markers and have intense reactivity with CK7, p63 and high molecular weight kininogen
(HWCK). The only CDC lacking expression of renal markers segregated to group D.
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expression of S100A1, INI-1, vimentin, AMACR, pre-
dominant lack of CK7 expression, PAX8 reactivity
greater than PAX2 and no expression of p63 or HMCK.
The subset of CDC (three of six, 50%) included in this
cluster is characterized by lack of expression with CK7
and HMCK staining, strong PAX8 and INI-1 expression
and variable expression with vimentin. The majority of
PRCC (15 of 18, 83%) segregated into cluster B.
Group C is composed of both RMCs and a subset of
CDC (two of six, 33%), which as a cluster are defined by
intense staining with CK7, PAX8 and S100A1 and
PAX8 reactivity stronger than PAX2, lack of expres-
sion with p63, CD10, CA1X and variable expression
with HMCK and INI-1. The two CDCs included in this
group are characterized by strong expression of CK7
and PAX8, positive INI-1, variable expression of
vimentin and lack of staining with p63. Both RMCs
lack INI-1, vimentin and p63 expression and are
strongly positive with CK7 and PAX8.
All the UCs (18 of 18, 100%) and a single CDC
segregated into group D, which is characterized by
intense staining with CK7, p63, HMCK and INI-1,
variable expression of S100A1 and a predominant lack
of reactivity with renal markers RCC antigen, vimentin,
PAX2 and PAX8. The single CDC that segregated in
this group was negative with p63, PAX2 and PAX8.
Several overlapping expression patterns were delin-
eated by the initial unsupervised cluster analysis of the
panel of antibodies examined. Three sets of antibodies
(CD10 and CAIX, PAX2 and PAX8 and HMWK and
p63) (see Table 2) clustered together among the four
tumour types (see Figure 1).
The initial unsupervised cluster plot (Figure 1) along
with expression percentages of the 11 antibodies for
four tumour types was reviewed and antibodies with
significant overlap or minimal impact in distinguishing
between the four types of renal tumours were removed.
An unsupervised cluster analysis with a select and
limited panel that included p63, CK7, vimentin, INI-1
and PAX8 was performed (see Figure 2).
The cluster plot of the select antibody panel sepa-
rated all the cases into four distinct groups at the third
division point of the cluster tree.
Cluster A is composed exclusively of both RMCs
characterized by strong expression of CK7 and PAX8
and lack of staining with p63, INI-1 and vimentin.
Clusters B and C are composed of a mixture of CRCC,
PRCC and CDC, but have different staining character-
istics. The 10 tumours segregating into cluster C,
composed predominantly of CRCC (six cases, 60%), a
subset of PRCC (two cases, 20%) and CDCs (two cases,
20%), are completely negative for CK7 and p63, show
predominantly strong INI-1 expression, have focal to
absent staining with vimentin and variable staining
with PAX8. In comparison, cluster B, composed of a
majority of CRCC and PRCC (75% and 89%, respec-
tively), a subset (50%) of CDC and a single case of UC, is
characterized by intense diffuse staining with vimentin
and INI-1, PAX8 positivity in the majority of cases, CK
7 expression in a subset of cases and no p63 expression
in all RCCs. The single UC in this cluster is positive for
p63 and segregated into this group based on strong
reactivity with both PAX8 and vimentin.
Finally, group D includes the majority of the UC (17
of 18, 94%) as well as one CDC, and is characterized
predominantly by intense and diffuse staining with
CK7, p63 and INI-1 and lacks vimentin and PAX8
expression. The single CDC case in this cluster is
negative with both PAX 8 and p63.
sensit iv ity, specif ic ity and posit ive
predictive values
The sensitivity and specificity of the antibodies that
comprise our panel for distinguishing collecting duct
carcinoma from its morphological mimics is presented
in Table 3.
P63 expression in UC was found to be both sensitive
and specific (100% and 100%, respectively) in distin-
guishing UC from all RCC subtypes. Lack of INI-1
Figure 2. Unsupervised cluster map of optimal panel of markers with urothelial carcinoma (UC), carcinoma of collecting ducts of Bellini
(CDC), renal medullary carcinoma (RMC), clear cell renal cell carcinoma (CRCC) and papillary renal cell carcinoma (PRCC). Antibodies are
arrayed at the top of the map and the various types of tumours are along the right side. The red line on the left is the level of the clustering
tree that separates the tumours into four groups. Group A, composed exclusively of both RMCs, is characterized by strong expression of CK7
and paired box gene 8 (PAX8) and lack of staining with p63, integrase interactor 1 (INI-1) and vimentin. Groups B and C are composed of
a mixture of CRCC, PRCC and CDC but have different staining characteristics. Group B, composed of a majority of CRCC and PRCC, a subset
of CDC and a single case of UC, is characterized by intense diffuse staining with vimentin and INI-1, PAX8 positivity in the majority of cases,
CK7 expression in a subset of cases and no p63 expression in all renal cell carcinomas (RCCs). The single case of UC, which is positive for p63,
segregated into this group based on strong reactivity with both PAX8 and vimentin. Group C, which is defined by a lack of p63 and CK7,
predominantly diffuse reactivity with INI-1 and variable expression of vimetin, and PAX8, is populated by a subset of CRCC, PRCC and CDC.
Finally, cluster D is nearly all UC, with the only CDC not expressing PAX8. The tumours in this cluster are defined by intense reactivity with CK7,
p63 and INI-1 with lack of staining for vimentin and PAX8.
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expression in RMC was both sensitive and specific
(100% and 100%, respectively) in distinguishing RMC
from UC and other subtypes of RCC. A combined panel
of p63, PAX8 and IN1-1 decreases sensitivity of UC
detection to 83% due to a small number of UC that are
positive for PAX8, but specificity remains at 100%. In
distinguishing CRCC and PRCC from UC, RMC and
CDC, positive reactivity with vimentin was found to
have a sensitivity of 89% and specificity of 88%. With
the addition of CK7 to vimentin, the sensitivity and
specificity drop to 73% and 68%, respectively. No
unique profile could separate CRCC from PRCC.
Utilizing the panel of select antibodies based on our
cluster analysis, the positive predictive value (PPV) for
the diagnosis of UC (p63+) compared to the four
subtypes of RCC with only p63 is 100%. When
distinguishing UC (p63+ ⁄ PAX8) ⁄ INI-1+) from CDC
(p63) ⁄ PAX8+ ⁄ INI-1+) or RMC (p63) ⁄ PAX8+ ⁄ INI-
1)), the PPV is 95%. The PPV of a tumour not being a
PRCC or CRCC with absent staining for vimentin is
89%. When positive reactivity for CK7 is added, the
PPV decreases to 70%. Lastly, in differentiating CDC
and RMC from CRCC and PRCC based on absence of
vimentin positivity, the PPV is 89%.
Discussion
The diagnosis of poorly differentiated, high-grade
carcinomas involving the renal sinus region is often
problematic. High-grade UCs of the upper urinary tract
frequently present with infiltrative masses that some-
times extensively involve the renal parenchyma mim-
icking RCCs. UC with glandular features shows
frequent morphological overlap with RCC, notably
CDC and RMC, both of which are rare but aggressive
subtypes of RCC. The major criteria for diagnosis of
CDC include epicentre of tumour in the renal medulla
as well as exclusion of UC involving the upper tract.1
Immunohistochemical reactivity of CDC with HMCK
and Ulex europaeus agglutinin lectin have been
included among major criteria for diagnosis of CDC;
however, they have limited utility, as both UC and CDC
are positive with these markers.1,4 We have evaluated
an expanded panel of immunohistochemical markers
including recent novel markers with the goal of
developing a select optimal panel that can distinguish
high-grade, poorly differentiated and infiltrative carci-
nomas involving the renal sinus region, with emphasis
on distinguishing invasive UCs of upper urinary tract
from high-grade RCCs, including CDC and RMC.
Our approach of cluster tree analysis to high-volume
immunohistochemical data5 confirms previous studies
that many markers (S100A1, CD10, AMACR and
CAIX) have overlapping staining patterns, limiting
their utility in day-to-day practice. We found that a
select panel of CK7, p63, vimentin, PAX8 and INI-1
offers the greatest sensitivity, specificity and predictive
value and defined our select optimal panel for sorting
out this differential diagnosis (see Figures 2 and 3).
Our results, using a broad panel as seen in the initial
unsupervised analysis (Figure 1), show almost all the
RCCs (45 of 46, 98%) segregating from UCs as a result
of lack of p63 expression, diffuse expression of vimentin
and variable expression of CK7, PAX 8, PAX 2 and RCC
antigen. In comparison, all the UC demonstrated strong
diffuse expression of p63 and the majority of UC (17 of
18, 94%) demonstrate strong expression of CK7. The
single case of CDC which segregated with all the UC
was negative with p63, PAX2 and PAX8. Thus, in our
cohort, strong, diffuse expression of p63 in UC was
Table 3. Sensitivity and specificity of antibodies that comprise the optimal panel in the differential diagnosis of urothelial
carcinoma and it morphological mimics
Differential diagnoses Panel markers Sensitivity (%) Specificity (%)
UC versus all RCC subtypes p63 (+) 100 100
UC versus RMC INI-1 (+) 100 100
UC versus CDC or RMC p63 (+), INI-1 (+) and PAX8 ()) 83 100
UC, CDC, RMC versus PRCC, CRCC Vimentin ()) 89 88
UC, CDC, RMC versus PRCC, CRCC Vimentin ()) and CK7 (+) 73 68
CDC, RMC versus PRCC, CRCC Vimentin ()) 75 92
CDC, Carcinoma of collecting ducts of Bellini; CRCC, clear cell renal cell carcinomas; INI-1, integrase interactor 1; PAX8, paired
box gene 8; PRCC, papillary renal cell carcinomas; RCC, renal cell carcinoma; RMC, renal medullary carcinomas; UC, urothelial
carcinoma.
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most valuable in distinguishing UC from RCC including
CDC and RMC.
Our expanded panel also included S100A1, AMACR,
CAIX and CD10, of which our results of S100A1, CD10
and AMACR are within the ranges of previous studies6–
10 (see Table 2). Interestingly, we found S100A1 to be
expressed by majority of UC and RCC and hence this
marker has limited utility in differentiating between
these tumours. The staining characteristics of CAIX
were slightly different from those reported previously
did not prove to be useful enough to be included in our
select panel. Recently, Gupta et al.11 examined CAIX in
renal epithelial neoplasms and found CAIX to be helpful
in differentiating between CDC and UC, as expression of
CAIX was present in the majority of UC. While the
CAIX expression in type 2 PRCC and CRCC in our study
was similar to Gupta et al., we found CAIX expression
in only a subset of UC (33%), rendering it of limited
utility in distinguishing it from CDC. Hence, these
immunohistochemical markers (S100A1, AMACR,
CAIX and CD10) did not add any discriminating power
and were of no significant utility.
PAX2 and PAX8 are members of the PAX gene
transcription factors family. PAX8, a more recently
described marker, is essential for thyroid, metanephron
and Mu¨llerian duct lineage commitment,12 while
PAX2 is essential for development of kidney during
fetal life.11 PAX8 is strongly positive (nuclear expres-
sion) in normal kidney and is expressed by collecting
ducts and differentiating nephrons. PAX2 has emerged
as a relatively sensitive and specific marker of RCC with
variable expression in the different subtypes of RCCs.10
PAX2 expression is noted in the majority of clear cell
RCCs and type 1 PRCCs; however, some subtypes of
RCC, including chromophobe RCC, tubulocystic RCC
and translocation-associated RCCs, show decreased
sensitivity with PAX2. Previous studies have reported
conflicting results regarding PAX2 expression in CDC;
Gupta et al.11 found no PAX2 expression in CDC (five
cases evaluated), while Ozcan et al.13 found all cases to
be positive with PAX2 (five cases evaluated). In our
study, PAX2 expression was noted in 50% (three of six)
of CDC. PAX2 was also positive in both cases of RMC
with focal staining in one case. PAX8 is emerging as a
specific markers for RCC,14 expressed by a majority of
RCCs.12,14 One of the interesting observations in our
study is the finding that PAX8 is overall a more
sensitive marker for the detection of RCCs, including
CDC compared to PAX2 (83% versus 50%, respec-
tively), and hence was included in our select panel. Of
all the high-grade RCCs in our cohort, 2% (one of 46,
one PRCC) cases were positive with PAX2 and negative
with PAX8, while 26% (12 of 46) were negative with
PAX2 and positive with PAX8. Overall, 11% of all
RCCs (five of 46, two CRCC, two PRCC and one CDC)
were negative with both markers. Our recent study,15
comparing utility of PAX8 and PAX2 in diagnosis of
RCC in cytology specimens, also showed similar find-
ings, with PAX8 showing slightly higher sensitivity
compared to PAX2 (88% versus 83%, respectively).
RCC antigen was excluded from our select panel
because of significantly decreased sensitivity compared
to PAX8 and PAX2.
HMCK and p63 show similar expression profiles,
with strong, diffuse expression in a majority of UC and
lack of reactivity in type 2 PRCC and CRCC. CDC, RMC
and UC show overlapping expression patterns with
HMCK, as almost a third of CDC and half of RMC in our
cohort are positive with this marker, confirming
previous studies;10,16 however, no p63 expression
was recognized in any CDC or RMC. The results of
our study support the utility of p63 as a sensitive and
specific marker of UC with diffuse nuclear expres-
sion.17,18 UC, CDC and RMC also show overlapping
staining patterns with CK7 and vimentin, with the
majority of these tumours showing predominantly
positive CK7 reactivity and negative expression with
vimentin. This is distinct from CRCC and type 2 PRCCs,
which tend to be predominantly negative with CK7 and
HMCK and are positive with vimentin. These findings
are in agreement with previous studies.10 In our
experience, the predominant utility of CK7 and vimen-
tin is to distinguish RMC, CDC and UC from type 2
PRCC and CRCC. The immunoprofile of CK7 (+) ⁄ vi-
mentin ()) supports a diagnosis of RMC or CDC or UC
(sensitivity 73% and specificity 68%). Interestingly, in
our cohort, vimentin alone could differentiate RMC and
CDC from PRCC and CRCC (sensitivity of 75%, speci-
ficity of 92%), yet the unsupervised cluster analysis was
not able to differentiate sufficiently between type 2
PRCC and CRCC. See Table 3 for details.
After reviewing the initial unsupervised cluster
analysis and excluding markers with limited discrim-
inating powers (S100A1, AMACR, CD10 and CAIX),
low sensitivity (PAX2 had lower sensitivity compared
to PAX8 but was more sensitive compared to RCC
antigen) and ⁄ or overlapping staining patterns com-
pared to other similar markers (RCC antigen, PAX2,
HMCK), a second unsupervised cluster analysis was
performed using a select panel composed of CK7, p63,
INI-1, vimentin and PAX8 (see Figure 3).
A panel of PAX8, p63 and INI-1 is optimal in
distinguishing UC from CDC and RMC as all three
tumours commonly show similar staining patterns
with CK7 and vimentin. PAX8 is a sensitive marker of
CDC and stains the majority of CDC (83%) and both
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RMCs in our cohort. It is more sensitive compared to
PAX 2, which only stained 50% of CDC and was focally
positive in one RMC. This finding is fully in keeping
with a recent study that analysed a large series of CDC
(21 cases) and found all CDC to be positive with PAX8.
The majority of UC (83%) involving the upper tract in
our study were negative for PAX8; a finding confirmed
by other studies (77–91%).12,19 Our experience with
p63 in UC involving upper urinary tract supports a
previous study18 that has shown p63 to be useful in
distinguishing UC from high-grade RCC, including CDC
and RMC (100% specificity for UC with no staining of
any RCC with p63). In our study, p63 was the single
most useful marker in the distinction of UC from RCC,
as no high-grade RCC in our cohort, including CDC and
RMC, showed reactivity with p63. INI-1 is most useful
in the distinction of RMC from UC and other subtypes of
RCC. Loss of the INI-1 tumour suppressor gene has
been shown in paediatric rhabdoid tumours of kidney.
A recent study20 demonstrated loss of heterozygosity
(LOH) of the hSNF5 ⁄ INI gene and a corresponding lack
of INI-1 immunoreactivity in RMCs. We analysed INI-1
expression in our cohort of cases and, as expected,
found strong, diffuse INI-1 expression in the vast
majority of UC, CDC CRCC and type 2 PRCC. As
expected, complete loss of INI-1 expression was
observed in both cases of RMCs. Interestingly, focal,
weak expression of INI-1 was observed in a subset of
CDC (two of six, 33%), while the remaining cases
showed diffuse, moderate to strong INI-1 expression.
While we did not observe any CDC case with complete
loss of INI-1 expression, a recent unpublished ab-
stract21 found INI-1 expression to be lost (20%) or
minimally expressed (10%) in a subset of CDC. These
UC
p63 CK7 Vimentin PAX8 INI–1
RMC
CDC
CRCC
PRCC
Figure 3. Representative examples of the tumours involving the renal hilum and their staining patterns as shown with the select optimal
panel of antibodies comprising of CK7, p63, vimentin, paired box gene 8 (PAX8) and integrase interactor 1 (INI-1).
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findings, which suggest that at least a subset of CDCs
may be related to RMCs, can be explored with
molecular studies.
An immunoprofile of PAX8 ()) ⁄ p63 (+) ⁄ INI-1 (+)
supports the diagnosis of UC involving upper urinary
tract (sensitivity 83%, specificity 100%), a PAX8
(+) ⁄ p63 ()) ⁄ INI-1(+) immunoprofile supports a diag-
nosis of RCC and favours CDC (sensitivity 88%, speci-
ficity 100%), while an immunoprofile of PAX8 (+) ⁄ p63
()) ⁄ INI-1()) supports a diagnosis of RMC in the correct
clinical setting (sensitivity 100%, specificity 100%). The
study by Albadine et al.19 found p63 positivity in a small
subset (three of 21, 14%) of CDC, a finding not noted in
our cohort of CDCs. Thus, in the unusual scenario of
PAX8 (+) ⁄ p63 (+) immunoprofile, IHC alone may not
be able to distinguish UC definitively from CDC, as both
tumours are positive with INI-1. In these cases,
additional clinical information including positive urine
cytology, the presence of urothelial carcinoma in situ
along the renal pelvis, etc. may be useful features to
support a diagnosis of UC. A recent unpublished
abstract,22 which analysed 11 cases of RMC, found
PAX8 and p63 positivity in 100% and 58%, respec-
tively, and postulated that PAX8+ ⁄ p63+ immunopro-
file supports the diagnosis with a sensitivity of 58% and
specificity of 89%. However, both cases of RMC in our
cohort showed an immunoprofile of PAX8 (+) ⁄ p63 ()),
similar to other RCCs, including CDC, but lacked INI-1
expression, unlike other RCC subtypes and UC.
There are some limitations to our study. RMC, an
extremely uncommon but high-grade RCC arising in
the renal medulla and occurring almost exclusively in
young African American male patients with sickle cell
trait, has not been represented extensively in our study.
Another somewhat smaller drawback of our study is
the lack of inclusion of Ulex europaeus lectin agglutinin
in our expanded panel. This is not a significant
limitation, as previous studies9 have confirmed that
this marker is expressed by both UC and CDC and
therefore is not effective in distinguishing these entities.
In summary, we found a select panel of p63, CK7,
vimentin, PAX8 and INI-1 to be most useful in
distinguishing between high-grade carcinomas (UC,
CDC, RMC, type 2 PRCC and CRCC) involving the renal
sinus region. p63 is most useful in distinguishing UC and
its positivity separates all UC from RCC mimics including
CDC and RMC. UC, CDC and RMC can have overlapping
immunohistochemical profiles, but can be distinguished
by intense p63 expression in UC and lack of INI-1
expression in RMC. INI-1 expression is exclusively lost in
RMC and is expressed minimally in a subset of CDCs, an
interesting finding that requires confirmation with
molecular studies. PAX8 is also helpful in separating
UC, which is rarely reactive, from high-grade RCCs
involving the renal sinus region (CDC, RMC, type 2
PRCC and CRCC) which demonstrate increased levels of
expression. In addition, the sensitivity of PAX8 is
significantly greater compared to PAX2 for all RCC
subtypes. S100A1 is expressed by the majority of UC and
RCC and is not helpful in distinguishing UC from RCC.
Using the antibodies tested here, we did not identify a
unique immunoprofile differentiating PRCC from CRCC.
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